Devices

FDA-cleared miniature peripheral nerve stimulator powered by a worn Therapy Disc, cleared 2019 with later 510(k)s through 2024. Thin: 510(k) text only.

Catalog specification sheet - Peripheral nerve

Nalu neurostimulation system PNS

Record ID
BTSD-FDA-0023
Reviewed
2026-10-08
Interface
pni
Evidence stage
human

Independent, source-linked catalog sheet. Not a manufacturer-issued datasheet, regulatory decision or instructions for clinical use. Human evidence does not establish approval. Source-specific restrictions, conflicts and missing specifications are retained below.

Nalu neurostimulation system PNS

The Nalu system is a miniature implanted peripheral nerve stimulator with an eight-electrode lead, powered wirelessly by a worn Therapy Disc. This sheet uses the 2019 510(k) K183579 and the 2024 K232415 record. A 510(k) shows substantial equivalence, not efficacy.

Identity

FieldValue and source scope
DeviceNalu Neurostimulation System for Peripheral Nerve Stimulation: miniature implanted pulse generator, leads, externally worn Therapy Disc, trial system, clinician programmer and patient remote [1]
ManufacturerNalu Medical, Inc., Carlsbad, California [1]
Interface classWirelessly powered implanted peripheral nerve stimulator with lead electrodes [1]
OriginCommercial FDA-cleared device; 510(k) K183579 [1]
First demonstratedUnreported
First human implantUnreported
Species studiedHuman [1]
Regulatory status510(k) K183579 cleared March 29, 2019; later 510(k) K232415 decision 08/21/2024, substantially equivalent. Class II, product code GZF [1][2]
FunctionPeripheral nerve stimulation for severe intractable chronic pain of peripheral nerve origin, not for craniofacial pain [1]
Target tissuePeripheral nerves [1]

Geometry and architecture

FieldValue and source scope
Interface typeLead with eight cylindrical electrodes at the distal end, available integrated with the IPG or connected through ports [1]
Array layoutUnreported
Electrode count8 per lead; single or dual lead configurations [1]
PitchUnreported
Electrode lengthsUnreported
Shank width and thicknessUnreported
Tip and exposed site geometryUnreported
Contact coatingUnreported
InsulationUnreported
Insertion methodUnreported
Anchoring and fixationUnreported

Electrode and channel physics

FieldValue and source scope
Exposed site areaUnreported
Electrode materialPt/Ir electrodes, polyurethane insulation [1]
Impedance (with measurement frequency)Unreported
Noise floor or SNRUnreported
Recording modalityUnreported
Sampling rateUnreported
Stimulation capabilityUnreported
Charge injection limitUnreported
Reference and groundUnreported

Tissue interface and bioresponse

FieldValue and source scope
Target tissueUnreported
Insertion trauma and BBB disruptionUnreported
Vascular disruption riskUnreported
Micromotion sensitivityUnreported
Gliosis and encapsulationUnreported
Neuron loss near sitesUnreported
Foreign-body response mitigationUnreported
Typical failure modesUnreported

System architecture

FieldValue and source scope
Onboard electronicsCeramic hermetic IPG enclosure with feedthrough and printed circuit board, polyurethane-encapsulated wires and silicone overmold [1]
Data pathTherapy Disc powers and commands the implant by RF; the clinician programmer runs on an Android tablet over Bluetooth Low Energy [1]
Telemetry bandwidthUnreported
Sampling rateUnreported
PowerImplant has no battery in the description read; the externally worn Therapy Disc holds a rechargeable lithium-ion battery and is held by an adhesive clip or belt [1]
Thermal managementUnreported
Packaging and hermeticityUnreported
MRI compatibilityUnreported
Surgical complexityUnreported
Output connectorsUnreported

Performance envelope

FieldValue and source scope
Acute yieldUnreported
Chronic yieldUnreported
Stability over timeUnreported
LongevityUnreported
Revision and explant experienceUnreported
Adverse eventsUnreported
Notable demonstrationsUnreported

Clinical and preclinical evidence

FieldValue and source scope
Human subjectsUnreported
Preclinical cohortUnreported
Follow-up durationUnreported
IndicationsAdults with severe intractable chronic pain of peripheral nerve origin, as sole agent or adjunct; trial devices for no more than 30 days [1]
Trials and registriesUnreported
Primary outcomesUnreported
Key limitationsCleared by 510(k) on predicate equivalence; no clinical trial data in the sources read. Pulse parameter ranges appear in a multi-device comparison table and were not attributed to the Nalu device here, so they read Unreported [1]

Engineering tradeoffs

FieldValue and source scope
StrengthsUnreported
LimitationsUnreported
Scaling constraintsUnreported

Version boundary

Description is from K183579 (2019). K232415 (decision August 21, 2024) is the latest record read; its document was not read for specs. A separate Nalu spinal cord stimulation clearance (K233801) is not covered.

References

  1. FDA 510(k) clearance and summary, K183579.
  2. FDA 510(k) record, K232415.